CA2246431A1 - Expression recombinee de proteines a partir de lignees cellulaires secretoires - Google Patents

Expression recombinee de proteines a partir de lignees cellulaires secretoires Download PDF

Info

Publication number
CA2246431A1
CA2246431A1 CA 2246431 CA2246431A CA2246431A1 CA 2246431 A1 CA2246431 A1 CA 2246431A1 CA 2246431 CA2246431 CA 2246431 CA 2246431 A CA2246431 A CA 2246431A CA 2246431 A1 CA2246431 A1 CA 2246431A1
Authority
CA
Canada
Prior art keywords
amylin
cell
cells
gene
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2246431
Other languages
English (en)
Inventor
Christopher B. Newgard
Philippe A. Halban
Karl D. Normington
Samuel A. Clark
Anice E. Thigpen
Fred Kruse
Dennis Mcgarry
Christian Quaade
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagene Inc
University of Texas System
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/589,028 external-priority patent/US6087129A/en
Application filed by Individual filed Critical Individual
Publication of CA2246431A1 publication Critical patent/CA2246431A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à des procédés de production de polypeptides hétérologues tels que l'amyline, à l'aide de lignées cellulaires obtenues par génie génétique. L'invention se rapporte également à des procédés de manipulation de cellules pour obtenir un haut niveau d'expression, à des procédés de production à grande échelle de protéines hétérologues, à des procédés de traitement de maladies in vivo à l'aide de systèmes d'administration viraux et de lignée cellulaires de recombinaison, et à des procédés destinés à isoler de nouveaux récepteurs de l'amyline.
CA 2246431 1996-01-19 1997-01-17 Expression recombinee de proteines a partir de lignees cellulaires secretoires Abandoned CA2246431A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/589,028 1996-01-19
US08/589,028 US6087129A (en) 1996-01-19 1996-01-19 Recombinant expression of proteins from secretory cell lines
US2842796P 1996-10-15 1996-10-15
US60/028,427 1996-10-15

Publications (1)

Publication Number Publication Date
CA2246431A1 true CA2246431A1 (fr) 1997-07-24

Family

ID=26703682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2246431 Abandoned CA2246431A1 (fr) 1996-01-19 1997-01-17 Expression recombinee de proteines a partir de lignees cellulaires secretoires

Country Status (4)

Country Link
EP (1) EP0910578A2 (fr)
AU (1) AU718254B2 (fr)
CA (1) CA2246431A1 (fr)
WO (1) WO1997026321A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO1999035242A1 (fr) * 1998-01-12 1999-07-15 Betagene, Inc. Milieu de culture de cellules neuroendocrines
AU2219999A (en) * 1998-01-12 1999-07-26 Betagene, Inc. Methods for preparing and using immortalized human neuroendocrine cells
US6322962B1 (en) 1998-08-14 2001-11-27 Board Of Regents, The University Of Texas System Sterol-regulated Site-1 protease and assays of modulators thereof
EP2206720A1 (fr) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Protéines de fusion d'albumine
EP2261250B1 (fr) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. Protéines de fusion d'albumine et GCSF
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2513213C (fr) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Proteines hybrides d'albumine
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
EP1718665B1 (fr) * 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Polypeptides hybrides presentant des proprietes pouvant etre choisies
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2005077094A2 (fr) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Motifs de la famille de polypeptides pancreatiques et polypeptides les renfermant
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
WO2007055996A2 (fr) * 2005-11-03 2007-05-18 Liat Mintz Compositions, reactifs, kits et procedes pour le diagnostic, le controle et le traitement du desequilibre hormonal
EP1816201A1 (fr) 2006-02-06 2007-08-08 CSL Behring GmbH Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
RU2008147398A (ru) * 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
WO2010080494A1 (fr) * 2008-12-19 2010-07-15 Tercica, Inc. Procédés d'identification de produits de dégradation dans un échantillon polypeptidique.
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
JP5732078B2 (ja) 2010-03-04 2015-06-10 ベンタナ メディカル システムズ， インコーポレイテッド 音響エネルギーを使用して標本を処理するための処理システム
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9341639B2 (en) 2013-07-26 2016-05-17 Industrial Technology Research Institute Apparatus for microfluid detection
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
EP3933845A3 (fr) 2014-10-27 2022-06-22 Aseko, Inc. Gestion sous-cutanée de patient externe
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
EP3337402B1 (fr) 2015-08-20 2026-01-07 Glytec, LLC Conseiller de thérapie pour la gestion du diabète

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
ATE173022T1 (de) * 1991-08-08 1998-11-15 Amylin Pharmaceuticals Inc Produktion von peptid-amiden
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus

Also Published As

Publication number Publication date
WO1997026321A3 (fr) 1998-01-08
EP0910578A2 (fr) 1999-04-28
WO1997026321A2 (fr) 1997-07-24
AU718254B2 (en) 2000-04-13
AU1750597A (en) 1997-08-11

Similar Documents

Publication Publication Date Title
CA2246431A1 (fr) Expression recombinee de proteines a partir de lignees cellulaires secretoires
US6110707A (en) Recombinant expression of proteins from secretory cell lines
AU714852B2 (en) Methods and compositions for inhibiting hexokinase
CA2246268A1 (fr) Expression par recombinaison de proteines issues de lignees cellulaires secretoires
Chang et al. Delivery of recombinant gene products with microencapsulated cells in vivo
US5427940A (en) Engineered cells producing insulin in response to glucose
US5891717A (en) Methods and compositions for inhibiting hexokinase
HU219674B (hu) Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra
US5993799A (en) Methods of using genetically engineered cells that produce insulin in response to glucose
EP1928504B1 (fr) Therapie de gene dans le foie
KR20080036015A (ko) 글루코오스 유도성 인슐린 발현 및 당뇨병 치료 방법
JP2020535834A (ja) 遺伝子修飾されたベータ細胞による糖尿病の治療
AU687836B2 (en) Vectors for genetically engineered cells that produce insulin in response to glucose
CN120129753A (zh) 使用可溶性免疫检查点蛋白诱发免疫耐受的方法
US5792656A (en) Methods of preparing genetically engineered cells that produce insulin in response to glucose
AU783594B2 (en) Method of prophylaxis and treatment of diabetes
CA2186528A1 (fr) Cellules genetiquement modifiees en vue d'une transplantation
AU2006281912B2 (en) Liver-directed gene therapy
AU4720500A (en) Recombinant expression of proteins from secretory cell lines
CA2248638A1 (fr) Compositions et procedes d'inhibition de l'hexokinase
DAVIES ENGINEERING A SURROGATE (-CELL
TW201923070A (zh) 以基因改造β細胞治療糖尿病
AU1835801A (en) Recombinant expression of proteins from secretory cell lines

Legal Events

Date Code Title Description
FZDE Dead